Sherri Johnson

456 total citations
13 papers, 199 citations indexed

About

Sherri Johnson is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Sherri Johnson has authored 13 papers receiving a total of 199 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 7 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Sherri Johnson's work include HIV/AIDS Research and Interventions (13 papers), HIV Research and Treatment (7 papers) and HIV, Drug Use, Sexual Risk (7 papers). Sherri Johnson is often cited by papers focused on HIV/AIDS Research and Interventions (13 papers), HIV Research and Treatment (7 papers) and HIV, Drug Use, Sexual Risk (7 papers). Sherri Johnson collaborates with scholars based in United States, Thailand and South Africa. Sherri Johnson's co-authors include Mark A. Marzinke, Beatrice A. Chen, Charlene S. Dezzutti, Annaléne Nel, Ariane van der Straten, Craig W. Hendrix, Craig Hoesley, Lydia Soto‐Torres, Nicola Richardson‐Harman and Lori Panther and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Sherri Johnson

11 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sherri Johnson United States 6 152 96 65 54 34 13 199
Richard E. Haaland United States 10 177 1.2× 77 0.8× 100 1.5× 53 1.0× 23 0.7× 23 249
Chase A. Cannon United States 10 79 0.5× 37 0.4× 71 1.1× 65 1.2× 22 0.6× 26 207
Elizabeth Hellström United States 6 153 1.0× 24 0.3× 83 1.3× 26 0.5× 47 1.4× 6 173
Wutyi Aung United States 10 309 2.0× 217 2.3× 115 1.8× 63 1.2× 35 1.0× 14 355
Fabien Taieb France 9 101 0.7× 99 1.0× 78 1.2× 27 0.5× 8 0.2× 25 245
Gyde Steffen Germany 7 63 0.4× 55 0.6× 150 2.3× 47 0.9× 15 0.4× 15 230
Laura A.S. Quilter United States 8 33 0.2× 36 0.4× 100 1.5× 86 1.6× 39 1.1× 27 216
Nicolette A. Louissaint United States 7 227 1.5× 164 1.7× 120 1.8× 134 2.5× 62 1.8× 13 403
Marineide Gonçalves de Melo Brazil 10 237 1.6× 72 0.8× 186 2.9× 30 0.6× 85 2.5× 36 334
Diarmuid Nugent United Kingdom 7 59 0.4× 41 0.4× 139 2.1× 33 0.6× 29 0.9× 15 220

Countries citing papers authored by Sherri Johnson

Since Specialization
Citations

This map shows the geographic impact of Sherri Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherri Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherri Johnson more than expected).

Fields of papers citing papers by Sherri Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherri Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherri Johnson. The network helps show where Sherri Johnson may publish in the future.

Co-authorship network of co-authors of Sherri Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Sherri Johnson. A scholar is included among the top collaborators of Sherri Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherri Johnson. Sherri Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Riddler, Sharon A., Clifton W. Kelly, Craig Hoesley, et al.. (2024). A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. The Journal of Infectious Diseases. 230(3). 696–705. 1 indexed citations
2.
Bauermeister, José A., Albert Liu, Suwat Chariyalertsak, et al.. (2024). A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035. Journal of the International AIDS Society. 27(3). e26219–e26219. 1 indexed citations
3.
4.
Achilles, Sharon L., Clifton W. Kelly, Craig Hoesley, et al.. (2024). Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings. PLoS ONE. 19(6). e0304552–e0304552. 2 indexed citations
5.
Laborde, Nicole, Ellen Luecke, Craig Hoesley, et al.. (2022). Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women. AIDS Patient Care and STDs. 36(3). 97–105. 4 indexed citations
6.
7.
McGowan, Ian, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M. Brand, et al.. (2021). An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses. 38(4). 279–287. 9 indexed citations
8.
Bauermeister, José A., Sherri Johnson, Jonathan Lucas, et al.. (2021). Acceptability of a Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-033 Study). AIDS Education and Prevention. 33(5). 361–376. 5 indexed citations
9.
Liu, Albert, Holly Gundacker, Alex Carballo‐Diéguez, et al.. (2019). Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017). JAIDS Journal of Acquired Immune Deficiency Syndromes. 81(5). 516–520. 1 indexed citations
10.
Chen, Beatrice A., Jingyang Zhang, Holly Gundacker, et al.. (2018). Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. Clinical Infectious Diseases. 68(7). 1144–1151. 22 indexed citations
11.
Dezzutti, Charlene S., Nicola Richardson‐Harman, Lisa C. Rohan, et al.. (2016). Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Medicine. 95(28). e4174–e4174. 13 indexed citations
12.
Chen, Beatrice A., Lori Panther, Mark A. Marzinke, et al.. (2015). Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings. JAIDS Journal of Acquired Immune Deficiency Syndromes. 70(3). 242–249. 90 indexed citations
13.
Hladik, Florian, Adam Burgener, Lamar Ballweber, et al.. (2015). Mucosal effects of tenofovir 1% gel. eLife. 4. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard E. Haaland Breakdown of academic impact, for papers by Chase A. Cannon Breakdown of academic impact, for papers by Elizabeth Hellström Breakdown of academic impact, for papers by Wutyi Aung Breakdown of academic impact, for papers by Fabien Taieb Breakdown of academic impact, for papers by Gyde Steffen Breakdown of academic impact, for papers by Laura A.S. Quilter Breakdown of academic impact, for papers by Nicolette A. Louissaint Breakdown of academic impact, for papers by Marineide Gonçalves de Melo Breakdown of academic impact, for papers by Diarmuid Nugent
Rankless by CCL
2026